US Stock Market Movement: Praxis surges on October 19 as brokers turn bullish and neuropharmaceutical development progresses
Bitget异动解读2026/10/19 16:25Praxis October 19 Surge Analysis
Keywords: Broker bullish outlook, neurological drug development
1. On October 16, JPMorgan initiated coverage of Praxis for the first time, giving it an “Overweight” rating with a target price of $700.
2. On October 15, UBS initiated coverage of Praxis for the first time, giving it a “Buy” rating with a target price of $706.
(Disclaimer: This content is summarized from publicly available information by AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stocks on the move: Agios surges on October 19 due to sickle cell disease review and mitapivat.
INE crude oil futures main contract breaks 740 yuan/barrel, up 2.96% intraday
Netflix film chief Dan Lin will leave the company
Crypto prices
More
